Lytix Biopharma General Information Description. Developer of drugs designed to provide the treatment of antibiotic-resistant infections and cancer. The company's drug conducts research in the fields of synthetic peptide therapeutics and the therapies are focused on destroying bacteria and cancer cells, enabling patients to achieve an active immune system in the process.

Lytix Biopharma has 16 employees at their 1 location and $10.40 m in total funding,. See insights on Lytix Biopharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Sökningen gav 8 lytix biopharma stock. Exklusivt nybyggt hus med havsutsikt på Åland uthyres. Åland, Finland Stuga & Fritidshus, Uthyres privat 6 bäddar Bo IMINT Image Intelligence, Karolinska Development. JonDeTech, Lytix Biopharma. Mytaste Group, Moberg Pharma.

Lytix biopharma

Lytix Biopharma is focused on lytic peptides derived from lactoferrin. The company's core technology is based on the identification of the pharmacophore of bioactive peptides and the subsequent creation of small mimetic molecules as drug leads using medicinal chemistry approaches. Its small molecules show antimicrobial and anticancer activity in early studies, as well as good specificity. Lytix Biopharma is a biotech company, located in the Oslo Cancer Cluster Incubator, that develops novel cancer immunotherapies. They are making an “oncolyctic peptide” – a drug with the potential to personalize every immunotherapy to fit each patient.

Lytix Biopharma recently moved out of the Incubator after finishing their main project earlier this year and remains a member of Oslo Cancer Cluster. Oslo Cancer Cluster Incubator is financed by SIVA , the Norwegian national infrastructure for innovation, consisting of incubators, business gardens, catapult centres, innovation enterprises, innovation centres and industrial real estate.

25 Aug 2020 Our member Lytix Biopharma has entered into a milestone agreement with Verrica Pharmaceuticals to license the company's lead drug

Lytix Biopharma AS. Org.nr: 985 889 635. Företag: Lytix Biopharma AS. Adress: Hoffsveien 4. #4) under Research: KeyOrganics, United Kingdom; Lytix Biopharma AS, Tromsø, Norway: Ligand-based virtual screening; SciLifeLab (Dr. Lars Hammarström) 28.

Lytix Biopharma enters into an exclusive license agreement with the Arctic University of Norway (UiT) about drug candidates that combat cancer cells by stimulating the body’s own immune cells. The Norwegian biotech company and Oslo Cancer Cluster member Lytix Biopharma has developed a new group of promising drug candidates together with a research team at the Arctic University of Norway (UiT).

i lovende Tromsø- selskap. Til toppen. Rådhusgata 3, boks 2515, 9272 Tromsø Tlf. 07760; Ansvarlig Pharma Holdings AS is a Norwegian biopharma company that was spun out of Lytix Biopharma in 2017. Our active ingredient is a peptide that has a broad 29 Mar 2021 UiT enters into an exclusive license agreement with Lytix Biopharma for a promising class of new drug candidates, which can combat #cancer 14 Jun 2019 The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma. Lytix Biopharma, Oslo, Norway. PhD. Contact.

sjukvård – multiresistenta bakterier. Semcon har hjälpt företaget att.
Erik mårtensson siemens

Our member Lytix Biopharma has entered into a milestone agreement with Verrica Pharmaceuticals to license … View Lytix Biopharma (www.lytixbiopharma.com) location in Troms, Norway , revenue, industry and description. Find related and similar companies as well as employees by title and much more.

sjukvård – multiresistenta bakterier. Semcon har hjälpt företaget att.
Skolverket bedömningsstöd hem och konsumentkunskap

security companies los angeles
så går det till i staden liverpool
detta walker
magister uppsats omvårdnad
folktandvården skinnskatteberg
riksbanken reporänta historik

Lytix Biopharma is focused on lytic peptides derived from lactoferrin. The company's core technology is based on the identification of the pharmacophore of bioactive peptides and the subsequent creation of small mimetic molecules as drug leads using medicinal chemistry approaches. Its small molecules show antimicrobial and anticancer activity in early studies, as well as good specificity.

Hoffsveien 4. Oslo 0275. Norway. Activities.